Cell and gene therapies coming to India thanks to new research

18 August 2022

Cell and gene therapies could become more affordable in India thanks to a raft of new biotech startups in the country focused on this therapy area.

Research from Industry analyst GlobalData indicates that there are currently just four such candidates being developed in the country, including CAR-T cell therapies from Immuneel Therapeutics and ImmunoACT.

In addition, Stempeutics Research is developing the cell therapy stempeucel, currently in Phase III testing for osteoarthritis and diabetic foot ulcers, and in Phase II studies for Crohn’s disease.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK